Leerink Partners Initiates Coverage On Seaport Therapeutics with Outperform Rating, Announces Price Target of $35

Benzinga Newsdesk www.benzinga.com Positive 74.5%

Neg 0% Neu 0% Pos 74.5%

Leerink Partners analyst Marc Goodman initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Outperform rating and announces Price Target of $35.